Login to Your Account



$50M Milestone for FibroGen

FibroGen, Astellas Open Wide: Oral Anemia Drug to Phase III

By Randy Osborne
Staff Writer

Thursday, December 13, 2012

Wading into Phase III waters with a new class of anemia drugs, FibroGen Inc. and partner Astellas Pharma Inc. hope to show benefit with their orally given drug not only in the condition related to chronic kidney disease (CKD), but also in hypertension and elevated cholesterol.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription